Edison Investment Research - OPGEN INC (OPGN) OpGen - Shareholder votes on Curetis merger coming

Report

Edison Investment Research

Sean Conroy

OpGen - Shareholder votes on Curetis merger coming

In September, OpGen announced a merger with Curetis, a Germany-based molecular diagnostics company with a similar focus on infectious disease. Curetis has two main business lines, the Unyvero A50 high-plex polymerase chain reaction (PCR) platform for the diagnosis of infectious disease in hospital patients and the ARES AMR database (ARESdb), which includes data on 40,000 sequenced strains with a focus on resistant pathogens. Closure is dependent on certain conditions including approval by both OpGen and Curetis shareholders, currently expected by the end of January 2020.

03/12/2019 7 EN

Underlying

OPGEN INC

See profile

US68373L2088 United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

SmartInsider

Opgen Inc: 1 director

A director at Opgen Inc bought 25,000 shares at 0.850USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board mem...

Free Trial

January 27, 2022 January 27, 2022 1 EN

Edison Investment Research

OpGen - AMR Gene Panel clearance expected shortly

OpGen has announced that it submitted an updated 510(k) summary of its Acuitas AMR Gene Panel test in bacterial isolates to the FDA in June and believes that the review of the 510(k) clearance should be completed by the end of August (a timeline previously communicated to the company by the FDA). That said, given the ongoing pandemic, this timeline is not guaranteed. Also, OpGen continues to plan to initiate a clinical trial program for complicated urinary tract infections (cUTI) with the Unyvero platform in the coming weeks and for invasive joint infections (IJI) later in the year.

August 18, 2021 August 18, 2021 5 EN

Edison Investment Research

OpGen - AMR Gene Panel clearance expected shortly

August 18, 2021 August 18, 2021 5 EN

Intralot - Focus on business development in FY24

Intralot enjoyed good underlying trends in performance in FY23 with encouraging trends in its main countries of focus and further progress on profitability. The much-improved balance sheet and extension of debt maturities mean management can focus on the significant business development opportunities available in FY24 and beyond. The share price looks attractive in the absence of potential new contract wins, which could be materially enhancing to the valuation.

5h / 34m 5h / 34m 1 EN

Kate Heseltine

Kate Heseltine

Headlam Group - Strategy for growth in tougher market

Headlam Group has laid out an ambitious long-term revenue target of between £900m and £1bn, as it seeks to grow its share of the UK floor coverings distributor market. Despite a challenging backdrop due to the low level of residential housing transactions, management is seeking to expand each of its sales channels: Trade Counters, Larger Customers, Regional Distribution and Europe & Other. The FY23 results reflected the more challenging environment and the group trades at a discount to its long-term average EV/sales multiple for FY24.

April 23, 2024 April 23, 2024 1 EN

Alison Turner

Alison Turner

Lithium Power International - Termination of coverage

Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (ETX), Pharnext (ALPHA) and Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

April 23, 2024 April 23, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

OpGen - Shareholder votes on Curetis merger coming

Opgen Inc: 1 director

OpGen - AMR Gene Panel clearance expected shortly

OpGen - AMR Gene Panel clearance expected shortly

Intralot - Focus on business development in FY24

Headlam Group - Strategy for growth in tougher market

Lithium Power International - Termination of coverage

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe